MHRA targets pharmacy students and AI-device under-reporting as MedSafetyWeek begins

What happened

On 2 November 2026 the MHRA widened its 2026 patient safety essay competition to pharmacy students, tying it to MedSafetyWeek. The agency is urging Yellow Card reports on both medicines and devices. It also flagged low reporting rates for AI-enabled devices.

The records do not give the contest's prize, deadline or judging criteria, and they do not quantify the AI-device reporting gap. We do not know how many reports have been received, what 'low' means in numbers, or which types of AI-enabled device the MHRA has in mind. Teams should read the MHRA's own page before drawing conclusions.

The timing matters. MedSafetyWeek, the global campaign run with the Uppsala Monitoring Centre, runs 2–8 November. Several other agencies announced their participation in the same window.

Why the AI-device flag matters

The MHRA's observation is a signal about signal detection. A spontaneous reporting system can only surface problems that people recognise and report. AI-enabled devices may make that harder, because an unexpected output or a software-driven failure can look like clinical judgement or user error rather than a product problem. That is our interpretation, not something the MHRA statement says in the records.

What the record does support is that the agency treats device reporting as a distinct weak spot, separate from medicines. For marketing authorisation holders with combination products, companion software or device components, the practical question is whether complaint-handling and PV processes can recognise and route a device-type event as a possible safety report.

The wider campaign picture

The MHRA is not alone in its timing. Slovakia's ŠÚKL is backing the campaign with the message not to ignore side effects, and has restated how suspected reactions can be reported. The Czech SÚKL is supporting the Uppsala Monitoring Centre drive, and its headline describes it as a record campaign. The records do not say what that refers to. On 31 October, Germany's Paul-Ehrlich-Institut and BfArM said they back the campaign so that risks are spotted earlier.

Taken together, regulators are using one coordinated week to push the same message to patients and professionals. For PV teams, expect a possible rise in incoming spontaneous reports and enquiries around this period. The records do not say whether any agency expects a measurable increase.

Context: why reporting matters now

The same day's records show a range of safety issues that reach regulators through different routes.

On the medicines side, the EMA's safety committee PRAC has started a review of the flupentixol/melitracen combination (Deanxit). Belgium raised concerns about severe, long-lasting and possibly irreversible neurological and psychiatric side effects. AIFA's summary of the 28–30 October PRAC meeting says a separate review of human immunoglobulins is also under way, covering hypersensitivity reports linked to batches. The outcome of either review is not yet known.

On quality, Slovenia's JAZMP published a DHPC asking for careful visual inspection of Caelyx 2 mg/ml vials after incorrectly crimped aluminium seals were found. The headline refers to one batch, while the summary text refers to some batches, so the scope should be checked against the DHPC itself.

On devices, the FDA posted an early alert on B. Braun Streamline Bloodline Sets for Dialog+. According to B. Braun, a missed solvent step during assembly left the dialyzer connector inadequately bonded on three lots, risking leaks, blood loss and air entry during haemodialysis. The FDA also flagged as most serious a recall of four lots of Werfen's HemosIL AcuStar HIT-IgG(PF4-H) assay. Negative bias may not be caught by routine calibration and quality control, and a supply interruption is expected.

The records do not say how any of these issues was first detected, so we cannot link them to reporting volumes. They do show that product defects, hypersensitivity patterns and neuropsychiatric effects all need frontline staff to notice, document and report.

Who is affected and what to watch

QPPVs and PV leads at companies with devices or device-drug combinations have the most direct exposure to the MHRA's AI message. Hospital and community pharmacy teams are the target audience of the essay contest, and the MHRA's extension to pharmacy students suggests it wants the reporting habit established early in training.

Watch for the MHRA publishing any figures on AI-device reporting, and for how entries to the competition frame the problem. On the EU side, watch for the scope and timetable of the PRAC reviews of Deanxit and immunoglobulins. None of the records says whether any regulatory action will follow the campaign week itself.